MedTrace Logo

Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia

NCT02237534 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-02-25

No results posted yet for this study

Summary

The purpose of this study is to compare the effect of lanthanum carbonate and calcium carbonate on the progression of coronary calcification and vascular endothelial dysfunction.

Conditions

  • Renal Insufficiency, Chronic
  • Hyperphosphatemia
  • Bone Diseases, Metabolic

Interventions

DRUG

Lanthanum carbonate

DRUG

Calcium Carbonate

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Osaka University

    lead OTHER

Principal Investigators

  • Takayuki Hamano, MD, PhD · Department of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2023-03-31
Completion
2023-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02237534 on ClinicalTrials.gov